FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509053222> ?p ?o ?g. }

• W2509053222 endingPage "967" @default.
• W2509053222 startingPage "963" @default.
• W2509053222 abstract "No AccessJournal of UrologyUrinary Tract Infection/Vesicoureteral Reflux1 Mar 2017Polyacrylamide Hydrogel as a Bulking Agent for the Endoscopic Treatment of Vesicoureteral Reflux: Long-Term Results and Safety Sophie Ramsay, Anne-Sophie Blais, Fannie Morin, Katherine Moore, Jonathan Cloutier, and Stéphane Bolduc Sophie RamsaySophie Ramsay More articles by this author , Anne-Sophie BlaisAnne-Sophie Blais More articles by this author , Fannie MorinFannie Morin More articles by this author , Katherine MooreKatherine Moore More articles by this author , Jonathan CloutierJonathan Cloutier More articles by this author , and Stéphane BolducStéphane Bolduc More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.08.093AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Polyacrylamide hydrogel has been shown to offer good short-term success for the endoscopic treatment of vesicoureteral reflux. Our objective was to provide long-term results of its efficacy and safety. Materials and Methods: We performed a prospective study using polyacrylamide hydrogel to treat all grades of vesicoureteral reflux. Every patient underwent endoscopic injection of polyacrylamide hydrogel followed by 3-month postoperative renal ultrasound and voiding cystourethrogram. Renal ultrasound was repeated at 12 and 36 months. Treatment success was defined as the absence of de novo or worsening hydronephrosis and the absence of reflux. Safety elements included new or worsening hydronephrosis, calcifications of the injected material and urinary tract infections. Results: A total of 76 patients (123 refluxing renal units) were assessed. Median age at surgery was 45 months and median followup was 36 months. Median injected volume of hydrogel per refluxing renal unit was 1.0 ml. The overall success rate 3 months after a single injection was 71%. During long-term followup 68 of 70 eligible patients underwent 12-month ultrasound and 40 of 46 underwent 36-month ultrasound. No upper tract deterioration or bulking agent calcifications were reported. Nine (12%) and 2 patients (3%) presented with nonfebrile and febrile urinary tract infections, respectively. Conclusions: The success rate of polyacrylamide hydrogel for endoscopic treatment of vesicoureteral reflux is comparable to published results of dextranomer hyaluronic acid. The long-term safety data and potential lower cost of polyacrylamide hydrogel provide further support for the use of this nonparticulate bulking agent to treat reflux. References 1 : The detection and characterization of vesicoureteral reflux in the child. J Urol1992; 148: 1640. Link, Google Scholar 2 : Surgical intervention in children with vesicoureteric reflux: are we intervening too late?. Pediatr Surg Int2010; 26: 729. Google Scholar 3 : Medical versus surgical management for vesicoureteric reflux: the case for medical management. Can Urol Assoc J2010; 4: 276. Google Scholar 4 : Correction of experimentally produced vesicoureteric reflux in the piglet by intravesical injection of Teflon. Br Med J (Clin Res Ed)1984; 289: 5. Google Scholar 5 : Endoscopic bulking materials for the treatment of vesicoureteral reflux: a review of our 20 years of experience and review of the literature. Adv Urol2011; 2011: 309626. Google Scholar 6 : A new bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. J Urol1995; 154: 800. Link, Google Scholar 7 : A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women. BJU Int2006; 98: 100. Google Scholar 8 : Polyacrylamide hydrogel (Bulkamid(R)) for stress urinary incontinence in women: a systematic review of the literature. Int Urogynecol J2016; 27: 367. Google Scholar 9 : The application of endoscopic methods in the treatment of vesico-ureteral reflux in children with the use of polyacrylamide hydrogel “Interfall”. Klin Khir1999; : 53. Google Scholar 10 : Polyacrylamide hydrogel differences: getting rid of the confusion. J Drugs Dermatol2011; 10: 1370. Google Scholar 11 : Prospective study using a new bulking agent for the treatment of vesicoureteral reflux: polyacrylamide hydrogel. J Urol2013; 190: 1034. Link, Google Scholar 12 : Efficacy of dextranomer hyaluronic acid and polyacrylamide hydrogel in endoscopic treatment of vesicoureteral reflux: a comparative study. Can Urol Assoc J2015; 9: 202. Google Scholar 13 : Dynamic hydrodistention classification of the ureter and the double hit method to correct vesicoureteral reflux. Arch Esp Urol2008; 61: 882. Google Scholar 14 : Endoscopic treatment of vesicoureteral reflux: 11 to 17 years of followup. J Urol2002; 167: 1443. Link, Google Scholar 15 : Endoscopic management of vesicoureteral reflux: does it stand the test of time?. Eur Urol2002; 42: 598. Google Scholar 16 : New contralateral vesicoureteral reflux following dextranomer/hyaluronic Acid implantation: incidence and identification of a high risk group. J Urol2006; 175: 1097. Link, Google Scholar 17 : The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol2004; 171: 2413. Link, Google Scholar 18 : Treatment of vesicoureteral reflux by endoscopic injection of dextranomer/hyaluronic acid copolymer: preliminary results. J Urol2003; 170: 1541. Link, Google Scholar 19 : Long-term results of endoscopic treatment of vesicoureteric reflux with different tissue-augmenting substances. J Pediatr Urol2010; 6: 251. Google Scholar 20 : Single center experience with endoscopic management of vesicoureteral reflux in children. J Urol2006; 175: 1889. Link, Google Scholar 21 : Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics2010; 125: 1010. Google Scholar 22 : Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol2006; 175: 716. Link, Google Scholar 23 : Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients. AIDS Res Hum Retroviruses2015; 31: 817. Google Scholar 24 : Prospective study of polydimethylsiloxane vs dextranomer/hyaluronic acid injection for treatment of vesicoureteral reflux. J Urol2014; 192: 1794. Link, Google Scholar 25 : Volume changes and histological response to injected dextranomer/hyaluronic acid copolymer (Zuidex) and collagen (Contigen) in rats. Int Urogynecol J Pelvic Floor Dysfunct2008; 19: 247. Google Scholar 26 : Long-term effects of polyacrylamide hydrogel on human breast tissue. Plast Reconstr Surg2003; 111: 1883. Google Scholar 27 : Endoscopic treatment of vesicoureteral reflux in children with dextranomer/hyaluronic acid—a single surgeon's 6-year experience. Diagn Ther Endosc2010; 2010: 278012. Google Scholar 28 : Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol2001; 166: 1887. Link, Google Scholar 29 : Long-term followup of dextranomer/hyaluronic acid injection for vesicoureteral reflux: late failure warrants continued followup. J Urol2009; 181: 1869. Link, Google Scholar 30 : Long-term results after endoscopic VUR-treatment using dextranomer / hyaluronic acid copolymer—5-year experience in a single-center. Cent European J Urol2011; 64: 84. Google Scholar © 2017 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 197Issue 3 Part 2March 2017Page: 963-967 Advertisement Copyright & Permissions© 2017 by American Urological Association Education and Research, Inc.Keywordsvesico-ureteral refluxhydrogelureterpolyacrylamideurinary bladderMetricsAuthor Information Sophie Ramsay More articles by this author Anne-Sophie Blais More articles by this author Fannie Morin More articles by this author Katherine Moore More articles by this author Jonathan Cloutier More articles by this author Stéphane Bolduc More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2509053222 created "2016-09-16" @default.
• W2509053222 creator A5008361474 @default.
• W2509053222 creator A5023474207 @default.
• W2509053222 creator A5048897058 @default.
• W2509053222 creator A5062793982 @default.
• W2509053222 creator A5074298522 @default.
• W2509053222 creator A5086319460 @default.
• W2509053222 date "2017-03-01" @default.
• W2509053222 modified "2023-10-10" @default.
• W2509053222 title "Polyacrylamide Hydrogel as a Bulking Agent for the Endoscopic Treatment of Vesicoureteral Reflux: Long-Term Results and Safety" @default.
• W2509053222 cites W1447307234 @default.
• W2509053222 cites W1799738610 @default.
• W2509053222 cites W1966882782 @default.
• W2509053222 cites W1968277667 @default.
• W2509053222 cites W1969053909 @default.
• W2509053222 cites W1976101631 @default.
• W2509053222 cites W1977496121 @default.
• W2509053222 cites W1981201374 @default.
• W2509053222 cites W1983433884 @default.
• W2509053222 cites W1985501813 @default.
• W2509053222 cites W1989746940 @default.
• W2509053222 cites W2014586578 @default.
• W2509053222 cites W2018067309 @default.
• W2509053222 cites W2019286381 @default.
• W2509053222 cites W2042630900 @default.
• W2509053222 cites W2047229371 @default.
• W2509053222 cites W2055360065 @default.
• W2509053222 cites W2057840655 @default.
• W2509053222 cites W2058573135 @default.
• W2509053222 cites W2059015738 @default.
• W2509053222 cites W2093928396 @default.
• W2509053222 cites W2135103568 @default.
• W2509053222 cites W2148107495 @default.
• W2509053222 cites W2155196841 @default.
• W2509053222 cites W2178463413 @default.
• W2509053222 cites W2279662535 @default.
• W2509053222 cites W4243334900 @default.
• W2509053222 cites W4361745362 @default.
• W2509053222 cites W1997825947 @default.
• W2509053222 doi "https://doi.org/10.1016/j.juro.2016.08.093" @default.
• W2509053222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27575606" @default.
• W2509053222 hasPublicationYear "2017" @default.
• W2509053222 type Work @default.
• W2509053222 sameAs 2509053222 @default.
• W2509053222 citedByCount "6" @default.
• W2509053222 countsByYear W25090532222016 @default.
• W2509053222 countsByYear W25090532222017 @default.
• W2509053222 countsByYear W25090532222020 @default.
• W2509053222 countsByYear W25090532222021 @default.
• W2509053222 countsByYear W25090532222022 @default.
• W2509053222 crossrefType "journal-article" @default.
• W2509053222 hasAuthorship W2509053222A5008361474 @default.
• W2509053222 hasAuthorship W2509053222A5023474207 @default.
• W2509053222 hasAuthorship W2509053222A5048897058 @default.
• W2509053222 hasAuthorship W2509053222A5062793982 @default.
• W2509053222 hasAuthorship W2509053222A5074298522 @default.
• W2509053222 hasAuthorship W2509053222A5086319460 @default.
• W2509053222 hasConcept C121332964 @default.
• W2509053222 hasConcept C126322002 @default.
• W2509053222 hasConcept C126894567 @default.
• W2509053222 hasConcept C127413603 @default.
• W2509053222 hasConcept C141071460 @default.
• W2509053222 hasConcept C2777609623 @default.
• W2509053222 hasConcept C2778451229 @default.
• W2509053222 hasConcept C2778862431 @default.
• W2509053222 hasConcept C2779134260 @default.
• W2509053222 hasConcept C3020475014 @default.
• W2509053222 hasConcept C42360764 @default.
• W2509053222 hasConcept C43270747 @default.
• W2509053222 hasConcept C61797465 @default.
• W2509053222 hasConcept C62520636 @default.
• W2509053222 hasConcept C71924100 @default.
• W2509053222 hasConceptScore W2509053222C121332964 @default.
• W2509053222 hasConceptScore W2509053222C126322002 @default.
• W2509053222 hasConceptScore W2509053222C126894567 @default.
• W2509053222 hasConceptScore W2509053222C127413603 @default.
• W2509053222 hasConceptScore W2509053222C141071460 @default.
• W2509053222 hasConceptScore W2509053222C2777609623 @default.
• W2509053222 hasConceptScore W2509053222C2778451229 @default.
• W2509053222 hasConceptScore W2509053222C2778862431 @default.
• W2509053222 hasConceptScore W2509053222C2779134260 @default.
• W2509053222 hasConceptScore W2509053222C3020475014 @default.
• W2509053222 hasConceptScore W2509053222C42360764 @default.
• W2509053222 hasConceptScore W2509053222C43270747 @default.
• W2509053222 hasConceptScore W2509053222C61797465 @default.
• W2509053222 hasConceptScore W2509053222C62520636 @default.
• W2509053222 hasConceptScore W2509053222C71924100 @default.
• W2509053222 hasIssue "3 Part 2" @default.
• W2509053222 hasLocation W25090532221 @default.
• W2509053222 hasLocation W25090532222 @default.
• W2509053222 hasOpenAccess W2509053222 @default.
• W2509053222 hasPrimaryLocation W25090532221 @default.
• W2509053222 hasRelatedWork W1928154064 @default.
• W2509053222 hasRelatedWork W2010586526 @default.
• W2509053222 hasRelatedWork W2053881426 @default.
• W2509053222 hasRelatedWork W2078863227 @default.
• W2509053222 hasRelatedWork W2093254547 @default.

• next